戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y) for 30 days or LHRH antagonist Cetrorelix pamoate (100 microg/day) for 30 days and daily injection
2 mpounds identified in this screen: pyrvinium pamoate, a Food and Drug Administration-approved drug, a
3                       Treatment with oxantel pamoate-albendazole resulted in higher cure and egg-redu
4 ection was significantly higher with oxantel pamoate-albendazole than with mebendazole (31.2% vs. 11.
5 d the efficacy and safety profile of oxantel pamoate-albendazole when used in the treatment of T. tri
6 s drugs, such as the antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds
7 h-throughput screen and identified pyrvinium pamoate as a drug-promoting exon inclusion without editi
8                        We identify pyrvinium pamoate as a nuclear speckle rehabilitator that enhances
9 , to receive one of four treatments: oxantel pamoate at a dose of 20 mg per kilogram of body weight,
10 e, administered on consecutive days; oxantel pamoate at a single dose of 20 mg per kilogram; albendaz
11  treated with the anthelmintic drug pyrantel pamoate before vaccination.
12 hroism spectroscopy indicates that pyrvinium pamoate binds directly to the pre-mRNA and changes its s
13 dministration of the CK1 activator pyrvinium pamoate by in vivo injection immediately after ischemia
14                                      Oxantel pamoate had low efficacy against hookworm and A. lumbric
15            The in vivo efficacy of pyrvinium pamoate is further confirmed in a subcutaneous xenograft
16 riptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar).
17 ally toxic for CSCs, we focused on pyrvinium pamoate (PP), an anthelmintic drug with documented antic
18  In pre-clinical models, nanomolar pyrvinium pamoate protects against retinal degeneration and tauopa
19                                   Cetrorelix pamoate reduced serum LH in female rats and diminished L
20     Genome-wide analyses show that pyrvinium pamoate regulates >300 alternative exons that form secon
21 974, zamaporvint, and FDA-approved pyrvinium pamoate repurposed for cancer therapy.
22  CI, 2.20-5.16]), and tribendimidine-oxantel pamoate (RR, 4.06 [95% CI, 1.30-12.64]).
23 .97 [95% CI, .21-1.74]), albendazole-oxantel pamoate (RR, 5.07 [95% CI, 1.65-15.59]; dERR, 0.51 [95%
24         Finally, Raman spectra of an AZD2811-pamoate salt compared well with those of the formulated
25  actions of some agents that are prepared as pamoate salts.
26 een used in formulations of several drugs as pamoate salts.
27 antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds hydroxyzine pamoate
28 ydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM); and the peptide hormones triptore
29 il-PM); and the peptide hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar).
30 oate; the psychoactive compounds hydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM);
31 cancer and anthelminthic compound, pyrvinium pamoate, which has also been proposed to exert its actio
32                                    Pyrvinium pamoate, which inhibits Wnt signaling, promotes ESRP1 ex